This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myrexis To Provide Update On Heat Shock Protein 90 And Cancer Metabolism Inhibitor Programs At 102nd Annual Meeting Of American Association For Cancer Research

SALT LAKE CITY, March 17, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present nine posters at the 102 nd annual meeting of the American Association for Cancer Research (AACR), April 2 – 6, 2011, in Orlando, Florida.

The posters will highlight key preclinical findings from two of Myrexis' oncology programs: MPC-3100, its fully synthetic, orally-bioavailable, non-geldanamycin heat shock protein 90 (Hsp90) inhibitor, which is completing Phase 1 clinical studies in solid and hematological refractory cancer patients; and its unique cancer metabolism inhibitor, MPC-9528, which is currently in preclinical studies and has demonstrated dramatic tumor regression in animal models across multiple tumor types using a variety of dosing schedules.

Abstracts describing the upcoming presentations are available online at www.aacr.org.

MPC-3100:  
   
Poster Number: 2617
Title: MPC-3100, a Synthetic Hsp90 Inhibitor, Induces Biomarker Changes in vitro and in vivo
Date & Time: Monday, April 4, 2011; 1pm – 5pm
Location: Exhibit Hall A4-C, Poster Section 29
   
Poster Number: 2628
Title: Anti-Tumor Activity of MPC-3100, a Synthetic Hsp90 Inhibitor, in Combination with Erlotinib and Sorafenib
Date & Time: Monday, April 4, 2011; 1pm – 5pm
Location: Exhibit Hall A4-C, Poster Section 29
   
Poster Number: 3233
Title: Comparative in vitro and in vivo Metabolism of MPC-3100, an Oral Hsp90 Inhibitor in Rat, Dog, Monkey and Human
Date & Time: Tuesday, April 5, 2011; 8am – 12pm
Location: Exhibit Hall A4-C, Poster Section 15
   
Poster Number: 3237
Title: Evaluation of the Pharmacokinetics and Efficacy of a Novel Pro-Drug of the Hsp90 Inhibitor MPC-3100, Designed with Improved Solubility
Date & Time: Tuesday, April 5, 2011; 8am – 12pm
Location: Exhibit Hall A4-C, Poster Section 16
   
   
MPC-9528  
   
Poster Number: 577
Title: Co-Administration of Nicotinic Acid with the Nampt Inhibitor MPC-9528 Enhances Anti-Tumor Activity in Naprt Deficient Cancer Cells in Culture and in Xenografts
Date & Time: Sunday, April 3, 2011; 1pm – 5pm
Location: Exhibit Hall A4-C, Poster Section 25
   
   
Poster Number: 2551
Title: The Nampt Inhibitor MPC-9528 Synergizes with DNA Damaging Agents
Date & Time: Monday, April 4, 2011; 1pm – 5pm
Location: Exhibit Hall A4-C, Poster Section 27
   
Poster Number: 3526
Title: Basal NAD Levels and Nampt Expression Correlates with the Sensitivity of Tumor Cell Lines in vitro and in vivo to the Nampt Inhibitor MPC-9528
Date & Time: Tuesday, April 5, 2011; 8am – 12pm
Location: Exhibit Hall A4-C, Poster Section 27
   
Poster Number: 4386
Title: Administration of Nicotinic Acid Reduces or Prevents Adverse Effects of MPC-9528, a Potent and Selective Nampt Inhibitor
Date & Time: Tuesday, April 5, 2011; 1pm – 5pm
Location: Exhibit Hall A4-C, Poster Section 23
   
Poster Number: LB-393*
Title: The Cancer Metabolism Inhibitor MPC-9528 Induces Tumor Regression in Xenograft Models with Multiple Dosing Schedules
Date & Time: Tuesday, April 5, 2011; 1pm – 5pm
Location: Exhibit Hall A4-C, Poster Section 39
   
* Late-breaker poster  

About MPC-3100

MPC-3100 is a novel, fully-synthetic, orally-bioavailable, small-molecule inhibitor of heat shock protein 90 that is currently in Phase 1 clinical studies. MPC-3100 is structurally distinct from geldanamycin-derived Hsp90 inhibitors and this unique structure appears to reduce the off-target toxicities that are common to this group of drugs. In non-clinical studies, MPC-3100 demonstrated activity against multiple solid and hematological tumor cell lines, suggesting it may have the potential to treat a wide range of cancers. In the ongoing Phase 1 clinical study, MPC-3100 is administered orally on a daily, continuous schedule which non-clinical studies suggest may optimize drug exposure and improve outcomes.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs